Mitochondrial-targeted plastoquinone therapy prevents early onset muscle weakness that occurs before atrophy during ovarian cancer

Objective: Muscle loss with cancer causes weakness, worsens quality of life, and predicts reduced overall survival rates. Recently, muscle weakness was identified during early-stage cancer before atrophy develops. This discovery indicates that mechanisms independent of muscle loss must contribute to...

Full description

Bibliographic Details

Published in:	Molecular Metabolism
Main Authors:	Luca J. Delfinis, Shahrzad Khajehzadehshoushtar, Luke D. Flewwelling, Nathaniel J. Andrews, Madison C. Garibotti, Shivam Gandhi, Aditya N. Brahmbhatt, Brooke A. Morris, Bianca Garlisi, Sylvia Lauks, Caroline Aitken, Leslie Ogilvie, Stavroula Tsitkanou, Jeremy A. Simpson, Nicholas P. Greene, Arthur J. Cheng, Jim Petrik, Christopher G.R. Perry
Format:	Article
Language:	English
Published:	Elsevier 2025-09-01
Subjects:	Ovarian cancer cachexia Mitochondria Skeletal muscle
Online Access:	http://www.sciencedirect.com/science/article/pii/S2212877825001188